Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (265 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

265 publications

Palbociclib (PD-0332991) HCl Chemical Structure

CAS No. 827022-32-2

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 265 publications

Nat Med, 2021, 10.1038/s41591-020-01168-7

PubMed: 33462444 ( click the link to review the publication )

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108636

PubMed: 33472061 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

Neoplasia, 2021, 23(1):140-148

PubMed: 33316538 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )
Nat Commun, 2020, 11(1):5305

PubMed: 33082317 ( click the link to review the publication )

Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3215-3221

PubMed: 32606000 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cell Rep, 2020, 32(10):108102

PubMed: 32905768 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Haematologica, 2020, haematol.2020.249177

PubMed: 32855276 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):262

PubMed: 33243298 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):87

PubMed: 32787886 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):754

PubMed: 32934219 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )
Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2221-2232

PubMed: 32747423 ( click the link to review the publication )

Front Oncol, 2020, 10:563249

PubMed: 33072590 ( click the link to review the publication )

J Cell Sci, 2020, 133(18)jcs247940

PubMed: 32878943 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Sci Rep, 2020, 10(1):18489

PubMed: 33116269 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:501

PubMed: 33061853 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):941

PubMed: 32998722 ( click the link to review the publication )

Open Biol, 2020, 10(10):200200

PubMed: 33052073 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):89

PubMed: 32795346 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0236298

PubMed: 32701996 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):262

PubMed: 33243298 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

J Pathol, 2020, e5493

PubMed: 32558936 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )
Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa653

PubMed: 32761127 ( click the link to review the publication )

Anticancer Res, 2020, 40(12):6699-6712

PubMed: 33288563 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

PLoS Biol, 2019, 17(8):e3000203

PubMed: 31430272 ( click the link to review the publication )

PLoS Biol, 2019, 17(4):e3000228

PubMed: 31039152 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(25):4962-4976

PubMed: 30833638 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )
Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2019, 316(1):E135-E144

PubMed: 30512986 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )
Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11107-11117

PubMed: 31908479 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31399419 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )
Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(6):1597-1609

PubMed: 30089269 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0206368

PubMed: 30383785 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Oncotarget, 2018, 9(79):34990-34995

PubMed: 30405888 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )
Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Oncogenesis, 2017,

PubMed: 28504693 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83432-83445

PubMed: 29137354 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84743-84760

PubMed: 29156680 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55319-55331

PubMed: 28903422 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2419

PubMed: 27735950 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:20376

PubMed: 26847534 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

BMC Syst Biol, 2016, 10(1):73

PubMed: 27515956 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Sci Rep, 2015, 5:14391

PubMed: 26399741 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(9):1506-22

PubMed: 25733683 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140243

PubMed: 26460486 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Oncotarget, 2015, 6(29):28057-70

PubMed: 26356814 ( click the link to review the publication )

Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )
J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

J Virol, 2013, 87(8):4623-41

PubMed: 23408614 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78641

PubMed: 24265703 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )
Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	M2P6O2tqdmG\|ZTDBd5NigQ>?		NXP0cZBKOjRiaB?=		NX3uRnZWUW6qaXLpeIlwdiCxZjDDSGs1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2=	M2\PVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
COLO205	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV63e4N[PzJiaB?=		MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=>	M2jvUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
U937	NUDKNYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHXCRnU4OiCq		NEfOboFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO	Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MOLM13	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\0blczKGh?		MnrxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2MUGwN{c,OjR4NEGxNFM9N2F-
MOLM13	NIHK[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPBO\|IhcA>?		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	Mo\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MDA-MB-435	M3PJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV2yOEBp		NEjmSllKSzVyPUCuNVYh\|ryP	NWLad5VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFE5OzFpPkG1PFAyQDNzPD;hQi=>
K562	NEnWXZFEgXSxdH;4bYMhSXO\|YYm=		M1\mOVk3KGh?	MlX0SG1UVw>?	NHrMb5VKSzVyPUKg{txO	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
DU145	MleyR5l1d3SxeHnjJGF{e2G7		NWr1bYR7QTZiaB?=	NIDaU41FVVOR	MYHJR\|UxRTdwNTFOwG0>	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MDA-MB-231	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfqdXIyKM7:TR?=	NXTYZotFOjRiaB?=	NGLweJBFVVOR	NI\3RVhE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	M{LkOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
MCF7	NGWyWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrkNUDPxE1?	NYP1NItbOjRiaB?=	NVnuWWhsTE2VTx?=	M2jxW2NmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=>	M{fiblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
MCF7	NF\RUWhMcW6jc3WgRZN{[Xl?	NGP3T5Q2KM7:TR?=	MmrvNlQhcA>?	NV24XGVITE2VTx?=	MVHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET\|Qw[3mlbHnuSFEh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy	M13OXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
MDA-MB-231	M2DoNmtqdmG\|ZTDBd5NigQ>?	MVq1JO69VQ>?	MXWyOEBp	NIe4d\|hFVVOR	MoGzTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	NHy4SmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MDA-MB-231	M2LmcWZ2dmO2aX;uJGF{e2G7	MWexMVExKM7:TR?=	M1qwXlI1KGh?	NVXTfHpuTE2VTx?=	M3e1O4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	NY\XenFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVc2PjZpPkK0OFE4PTZ4PD;hQi=>
MCF7	MnK5SpVv[3Srb36gRZN{[Xl?	MXWxMVExKM7:TR?=	NGHLWHAzPCCq	NE\ybFFFVVOR	M3XGc4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MDA-MB-231	NYntT\|VpTnWwY4Tpc44hSXO\|YYm=	M{XmSFAvPS1zIN88US=>	Ml;pOFghcA>?	M1zMfGROW09?	MXfoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	NFfYb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MCF7	MY\GeY5kfGmxbjDBd5NigQ>?	Mo\wNE42NTFizszN	MYW0PEBp	MWfEUXNQ	MXXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	MlvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MOLM13	NX;6NIR7S0SNNDDpcohq[mm2aX;uJIF{e2G7		NXzKU3FFOjRiaB?=		MVPJR\|UxKD1iMD6wNVEh\|ryP	NELzcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
A2780	MkD0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWrpVVRqPzJiaB?=		MnL3S2k2OCB;IECuNFMzKM7:TR?=	NIHtOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
COLO205	NG\IWnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NGG3WZQ4OiCq		M2fNWGlEPTBiPTCwMlA{PiEQvF2=	M4HQfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
MV4-11	NFi4XZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGXHfm04OiCq		NE\jSoJIUTVyIE2gNE4xPSEQvF2=	NGH4d4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MOLM13	MonXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFL4dJM4OiCq		NEDmVmxIUTVyIE2gNE4xPjJizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
NB4	Mo\WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Moe3O\|IhcA>?		M1XzWGdKPTBiPTCwMlA3PiEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
PC3	M{DNVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWf6eFM3PzJiaB?=		NYHK[HRGT0l3MDC9JFAvODdzIN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
MOLM13	NYK1RmV6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M{XJS\|czKGh?		MUfJR\|UxKD1iMD6wPVYh\|ryP	NIfNc5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
MOLM13	Mn3SRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NUH1[3RCPzJiaB?=		Mn\JTWM2OCB;IECuNFk3KM7:TR?=	NYf5PHpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
MDA-MB-453	NFy5W41EgXSxdH;4bYNqfHliYYPzZZk>		NHT2d2k1QCCq		M4f2cmlEPTBiPTCwMlE{PyEQvF2=	NYPIXHBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0OFg6OTNpPkK3OFQ5QTF\|PD;hQi=>
U937	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MorqO\|IhcA>?		MlK4TWM2OCB;IECuNVQh\|ryP	M{PQSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
MDA-MB-435	NX;UcJJ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NYm5bmJIOjRiaB?=		NXHtTIljUUN3MDC9JFAvOTZizszN	NUjYToRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
MCF7	MoCyR5l1d3SxeHnjbZR6KGG\|c3H5		MYK0PEBp		M{nZS2lEPTBiPTCwMlI1KM7:TR?=	NHLTeGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S0PFkyOyd-Mke0OFg6OTN:L3G+
MDA-MB-453	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4PBflczKGh?		M2fZW2dKPTBiPTCwMlMzPiEQvF2=	NGrrcFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MCF7	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoHWO\|IhcA>?		MYfHTVUxKD1iMD61OVch\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
MDA-MB-231	MmL6R5l1d3SxeHnjbZR6KGG\|c3H5		NF6xfow1QCCq		MoHtTWM2OCB;IECuOVgh\|ryP	M4HoZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NES4PVE{Lz5{N{S0PFkyOzxxYU6=
M229	M{i3V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIPkbo44OiCq		M4n6fmdKPTBiPTCxMlIzKM7:TR?=	NFPvbW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
M238	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NG\yZm84OiCq		NUX6WVhuT0l3MDC9JFEvQTdizszN	NW\vZmlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
M249	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnTaO\|IhcA>?		MlzMS2k2OCB;IEGuPVkh\|ryP	Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
K562	NXvUcIRGS3m2b4TvfIlkcXS7IHHzd4F6		NEXJdXc6PiCq		NFfNeYhKSzVyIE2gNkDPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
M249R	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoH0O\|IhcA>?		NFfpeJZIUTVyIE2gNk46PiEQvF2=	NXPYb\|JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
MOLM13	MmPMSmxVOyCrbnjpZol1cW:wIHHzd4F6		M3PrS\|I1KGh?		MY\JR\|UxKD1iMzFOwG0>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2MUGwN{c,OjR4NEGxNFM9N2F-
MDA-MB-468	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NX;K[YdPOjRiaB?=		MoPSTWM2OCB;IEOg{txO	NV;meYFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
C4-2B	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M17oPVczKGh?		M2nz[GdKPTBiPTC0MlE2KM7:TR?=	MlPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
DU145	NWi0[oIxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;ocVczKGh?		M{DpeGdKPTBiPTC1Mlc6OiEQvF2=	NF:zeJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MDA-MB-468	M1HTcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYK3NkBp		NHnySpJIUTVyIE2gOU46PiEQvF2=	M4H2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
BPH1	NFW1c2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHi4RlQ4OiCq		MXvHTVUxKD1iNz60OFIh\|ryP	Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
DU145	NImxbI1EgXSxdH;4bYNqfHliYYPzZZk>		M37rTVk3KGh?		M4PGeGlEPTBiPTC3MlUh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MRC5	MmrMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MonPO\|IhcA>?		MVTHTVUxKD1iMUCg{txO	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
697	NEjD[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF2OD6zPEBvVQ>?	MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fVOWlEPTB;OU[uNFQhdk1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB69	NYP4ZlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrDS2FKSzVyPUG2NU45KG6P	NWXJdGdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EoL-1	NHW1ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnaTWM2OD1zOEeuNlYhdk1?	MlTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BHT-101	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjuU3k1UUN3ME2xPVgvOjVibl2=	M13GdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-NEP-1	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\J[lZKSzVyPUKyNE4xOiCwTR?=	M1rGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MHH-NB-11	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTJ{MD6xPUBvVQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
AsPC-1	NV7DSGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLTTWM2OD1{NUKuOVMhdk1?	M{LyO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ES1	NWnmfJpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ3Nj6yOUBvVQ>?	NV3rfmlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LAMA-84	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXxTWM2OD1{NUiuNVkhdk1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MOLT-16	NWWySZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfvWWtKSzVyPUK1PE41QSCwTR?=	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES7	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2T4ZWlEPTB;MkezMlA6KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KY821	NIPZc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHKTWM2OD1\|MUSuNUBvVQ>?	MnTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RT-112	NGPUZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33tc2lEPTB;M{KxMlA2KG6P	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HL-60	M2f4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHObWFNUUN3ME2zOFAvPjZibl2=	M1vZeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MOLT-4	NHy4XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPVe3FKSzVyPUO0OU4yOyCwTR?=	MmHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KARPAS-45	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjr[XBxUUN3ME2zO\|YvOTZibl2=	NGC3UIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-N-AS	NV;ZXoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjHS5hKSzVyPUO4O{45OyCwTR?=	NHfwbYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CTB-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXy1R4dLUUN3ME20NFUvODJibl2=	NGXzVZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NKM-1	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnCTWM2OD12MUGuPFkhdk1?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HTC-C3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;EeZJWUUN3ME20N\|IvQTVibl2=	NGHjV4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BE-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTR2ND6yO{BvVQ>?	NVGyZWxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KOSC-2	NVLXbY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTR4Nj65JI5O	MmryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB14	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGL4cnFKSzVyPUS4N{42QCCwTR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-27	M3fP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGewTIlKSzVyPUS5OE42QSCwTR?=	NHuyTGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
H9	NYTFOZZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LF[GlEPTB;NEm1MlQ{KG6P	NGixRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RS4-11	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnoTWM2OD13MESuO\|Mhdk1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
PA-1	M3:2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7VOIFKSzVyPUWwPU45PiCwTR?=	NYDHOJlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MV-4-11	M{Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\UfIpKSzVyPUWxN{45PSCwTR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
OS-RC-2	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvxTWM2OD13MkGuOlIhdk1?	M2\jdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RPMI-8226	NITsNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorWTWM2OD13Mk[uPFYhdk1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HGC-27	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrVTWM2OD13NkSuPVkhdk1?	NEXzVXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CHP-212	M1jhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnvOVVKSzVyPUW5N{42QSCwTR?=	M4rEPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NB10	NXPKfZByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTV7OT6xPEBvVQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HH	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTmN3N[UUN3ME21PVkvPDNibl2=	MkGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-16	NXXXXWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTjWpdnUUN3ME22NFMvPTJibl2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ES8	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M376d2lEPTB;NkC1MlIyKG6P	MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HAL-01	M1vIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTZyNT62O{BvVQ>?	NWrmeVloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A204	NYr4U41HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLYRlRqUUN3ME22N\|MvQTFibl2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	M364Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\iTWM2OD14M{[uPVkhdk1?	NHvaeVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EM-2	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnUfIJtUUN3ME22OVAvPjRibl2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
BV-173	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1yxR2lEPTB;NkWyMlQ5KG6P	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ONS-76	NU\Bflc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELiVWVKSzVyPU[3O{45OiCwTR?=	M4HSOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KM-H2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTZ7NT61OEBvVQ>?	NVfJVppMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
D-263MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPZdppNUUN3ME23NVcvOTJibl2=	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES3	NXrkdFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3kOXZTUUN3ME23NlgvQTNibl2=	Mmi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnS[XJKSzVyPUezNk4zPyCwTR?=	M3jOZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NBsusSR	NX6wN2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfsTWM2OD15NEKuPVkhdk1?	NF\S[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H520	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLnTWM2OD15NE[uOVIhdk1?	M4qzZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ES5	M{XlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XuemlEPTB;N{WyMlghdk1?	M2q4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
T-24	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnrTWM2OD15N{iuO\|Ehdk1?	NYGz[lVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW962	MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTSR2txUUN3ME24NFgvPjNibl2=	MlrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-3	M{XJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi3VpVKSzVyPUiwPE44PiCwTR?=	MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RXF393	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrreYFKSzVyPUixNk44QSCwTR?=	Mn;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
U251	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRThzMz64PEBvVQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAMA-1	NVXa[3JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PHdWlEPTB;OEOzMlk1KG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
JVM-3	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXkTWM2OD16NUGuO\|ghdk1?	Mnf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
COLO-800	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L3dmlEPTB;OEm3Mlc5KG6P	MmrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
OVCAR-5	NF[zWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\RVIxKSzVyPUmwNE4yKG6P	NEPtTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LB1047-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTl{Nz61OkBvVQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW954	M2HPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfWc4dKSzVyPUmyPU41OSCwTR?=	M3rpc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	NWHFNmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTl\|Nj6wOkBvVQ>?	M3TLR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Mewo	M4mydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT3bI1IUUN3ME25N\|YvPiCwTR?=	NInhNpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1770	NUDQTFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWC1[Y4{UUN3ME25OFAvPTVibl2=	Mmr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HO-1-N-1	M3raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzhXm81UUN3ME25OlIvQDFibl2=	NVXHWVdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HSC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnacoNKSzVyPUm2Ok41QCCwTR?=	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TYK-nu	M{D6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTLTWM2OD17OUiuNlUhdk1?	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-150	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHxTWM2OD1zLkCwNFc3KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SN12C	NX[yNHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFwMEC4O\|Uh\|ryP	M3TCTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MOLT-13	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTFwMEG0NlEh\|ryP	MnHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	NEHFfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLYTWM2OD1zLkC0PFEzKM7:TR?=	M2fUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DB	NHnhdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofvTWM2OD1zLkC3Nlc{KM7:TR?=	M{juR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-39	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XyUGlEPTB;MT6wO\|UzOiEQvF2=	NVqwWYVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A3-KAW	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ziV2lEPTB;MT6wPFQxQCEQvF2=	MnHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CHP-134	NIfpbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvoTWM2OD1zLkGxPFA4KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TGW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;TdoEyUUN3ME2xMlEzOzl3IN88US=>	NHLU[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
QIMR-WIL	NW\FdIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFwMUOxN\|Qh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	NGHNU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ryTGlEPTB;MT6xOlM2PCEQvF2=	MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	NHnRcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwMUexPFYh\|ryP	M2CxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MHH-ES-1	M2fuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HKbmlEPTB;MT6xO\|k5PiEQvF2=	Mn7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTFwMUi2NkDPxE1?	NXzLUmdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ML-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjNRXFKSzVyPUGuNlA4OzRizszN	MnruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
COR-L23	NX7PZ2FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\tZ5ZrUUN3ME2xMlIzQTN\|IN88US=>	M2i4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BFTC-905	NEGycVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PXeGlEPTB;MT6yOFI3PyEQvF2=	NUjBeHhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
Hs-578-T	NEflTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPWRlFKSzVyPUGuNlU5OTdizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KG-1	M4fzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HPR2lEPTB;MT6yOlY5PiEQvF2=	NWTa[\|dVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOzeYZCUUN3ME2xMlI6OzN6IN88US=>	MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A549	M1;RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoH2TWM2OD1zLkK5N\|k6KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
COLO-741	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDTTWM2OD1zLkOyNFg6KM7:TR?=	NIHVNGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
PC-3	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTkVmhKSzVyPUGuN\|UzOjFizszN	NVP5dod2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HOS	NF7sRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3SVFlKSzVyPUGuN\|UzQTZizszN	MlfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HT-1080	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjWfJJKSzVyPUGuN\|c2OTlizszN	M4DjZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TE-8	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFwNEG3O\|Qh\|ryP	M{f5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BHY	M3jFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPqWYNEUUN3ME2xMlQ3QTJ\|IN88US=>	NX3lclYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BB65-RCC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\ZTWM2OD1zLkWwOVI5KM7:TR?=	M2XOXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HN	NHzj[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwNUSwO\|Eh\|ryP	NXe5N\|ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H441	NEjsXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\DTWM2OD1zLkW0PVA4KM7:TR?=	MoHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-8866	NIHIeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfWe41LUUN3ME2xMlU5PTB5IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-62	NYDVdINIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUf6[YhFUUN3ME2xMlYxQDZ{IN88US=>	NI\vbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MG-63	NYL0NGhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmriTWM2OD1zLk[xPFE{KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-LU-1	M{jLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnERnQ2UUN3ME2xMlYzOTV{IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
BCPAP	NHzRfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn6zTWM2OD1zLk[2OFU4KM7:TR?=	NWno[XRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
22RV1	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7MTWM2OD1zLk[3PFQ{KM7:TR?=	NFTvPYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
T47D	NFPHd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwNkiwOlEh\|ryP	NGDlco09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MSTO-211H	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLvTWM2OD1zLk[5OlA{KM7:TR?=	NVGwc4NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
DEL	NXi0UHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwN{CyO\|Mh\|ryP	Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
H4	NVL3cJU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XC[GlEPTB;MT63N\|IyOiEQvF2=	M{\ZN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-51	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL2TWM2OD1zLke0PFU2KM7:TR?=	NV\0[phrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ABC-1	M1TUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLOW\|FHUUN3ME2xMlc5PTh{IN88US=>	NWXuN49QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	M1:3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVviRmtRUUN3ME2xMlc6PTR{IN88US=>	NWPweZdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
YKG-1	M1PZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonyTWM2OD1zLkixNFYyKM7:TR?=	NFvyVlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KM12	NWD1NoVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnjTWM2OD1zLkixOlAzKM7:TR?=	Mn3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
L-363	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFwOEe0NVIh\|ryP	M4jTVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KU812	M{CzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUftPHUyUUN3ME2xMlg6Ojh{IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LOXIMVI	NEnYTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwOUGyNlgh\|ryP	NF:2Vo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
G-401	NWjuPJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGi5WpRKSzVyPUGuPVI1OjhizszN	M4CwXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW780	M1Xtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nTVWlEPTB;MT65OlI1PiEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW872	NX\MbIYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknFTWM2OD1zLkm4N\|Mh\|ryP	M3znZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NB7	M3ryNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTR[oZKSzVyPUGuPVk{OjNizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
T98G	M4L6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLlTWM2OD1{LkCwOlY3KM7:TR?=	NXnrdFN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1710	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJwME[5OFUh\|ryP	MoTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1573	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJwMEeyPVgh\|ryP	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KE-37	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7URldTUUN3ME2yMlA5QTVzIN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
786-0	NX7hOI5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlryTWM2OD1{LkG1OFM6KM7:TR?=	NIKwRXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SAS	NH3ST5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PHSmlEPTB;Mj6yNFM4PCEQvF2=	NUH5OWFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAL-54	M37yRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[wS5RKSzVyPUKuNlA1OTNizszN	NYfINJhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SF268	NGW5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPSSodlUUN3ME2yMlI{OTJ{IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW620	NITDVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTkN\|VKSzVyPUKuNlYyPjlizszN	M2PMVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MN-60	NGfBT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnmTWM2OD1{LkOxNFYh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EFO-27	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrEWXlKSzVyPUKuN\|IxPThizszN	MlvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H747	M3fFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzhTWM2OD1{LkOyNVk6KM7:TR?=	NUHkcolJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HCC2218	NVrETVRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJwM{WzO\|Qh\|ryP	Ml;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MIA-PaCa-2	NFjjeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3WwbGlEPTB;Mj6zOlQ{PyEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SJSA-1	M1;6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTJwM{e3PVYh\|ryP	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RKO	NH\ITGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[0TWM2OD1{LkO4OFk3KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB6	NGOxUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3ncZRKSzVyPUKuOFA{PzRizszN	Ml;JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvyPYxQUUN3ME2yMlQ2PDJ{IN88US=>	NUO3XoFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EGI-1	M4TlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHDTWM2OD1{LkS2PFg{KM7:TR?=	NVXXSZNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CTV-1	NIjZcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJwNUK3O\|Mh\|ryP	NXnpeY15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1355	NIDOT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwNUW5OVEh\|ryP	Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GT3TKB	NFr4UFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37kXGlEPTB;Mj61PVE6QSEQvF2=	NFvZU4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-HEP-1	NGG4UWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXMUIpKSzVyPUKuOVkzPjZizszN	MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GAMG	NVjVOnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\YOmlEPTB;Mj61PVM6PCEQvF2=	NYnO[\|FVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-MES-1	NIGzPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XXcGlEPTB;Mj62NVgxOyEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RO82-W-1	NF6yTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnRTWM2OD1{Lk[yNFU4KM7:TR?=	NH34R3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ECC10	NX\6fnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJwN{CyNFYh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MCF7	NXLneGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJwN{G0OlQh\|ryP	NF7iR3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-283MED	NVfpdpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJwN{K0N{DPxE1?	NWX3SllXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RPMI-7951	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTDTWM2OD1{Lke1Olk1KM7:TR?=	MoPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	M2HTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTucWlKSzVyPUKuO\|cxQTlizszN	NWnqSnZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KGN	NUL6Wo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7KTWM2OD1{LkixPFg1KM7:TR?=	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NUGC-3	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEGzWlZKSzVyPUKuPFI2ODVizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H292	M1v5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwOEWwOVMh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
Becker	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\PUHZMUUN3ME2yMlk2QDN{IN88US=>	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1299	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTNwMEWyOlMh\|ryP	M2izS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ETK-1	NVPTenY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPVTWM2OD1\|LkC1OFMh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TK10	M{XOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3qdYlSUUN3ME2zMlIxOTZ3IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	NEn3[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3i5e2lEPTB;Mz6zOlQ5QCEQvF2=	NHHOXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
YH-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTDTWM2OD1\|LkS0NFc6KM7:TR?=	M3S5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DU-145	M4\3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTNwNE[yOlkh\|ryP	NV25NWVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1088	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC4TWM2OD1\|LkS3OFch\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HOP-92	NV;IZ2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXGXWoyUUN3ME2zMlUxOzR{IN88US=>	NVSzRZdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KP-N-YS	NE\WfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTNwNkKxN\|kh\|ryP	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H460	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTNwNk[3N{DPxE1?	MlH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
U-2-OS	M{XDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rKfWlEPTB;Mz63NlU{PSEQvF2=	M2\0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
A101D	NVzkTFNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn62TWM2OD1\|Lke2PVM3KM7:TR?=	M1XmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-231	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTNwOEG5OVEh\|ryP	NXiwdXBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
IST-MES1	NWDGXG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTNwOEOyJO69VQ>?	NYHpRmpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COR-L105	NUPa[IdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLHboc4UUN3ME20MlAyQCEQvF2=	M4HmOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1437	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j6ZmlEPTB;ND6wNlMxOiEQvF2=	Ml;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAL-85-1	NVjsfVdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC0TWM2OD12LkCyOFYyKM7:TR?=	NFvSe\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MZ1-PC	NGrNT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHe5TFRKSzVyPUSuNVg2PTZizszN	NIf5OpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
VM-CUB-1	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknTTWM2OD12LkOxNlg1KM7:TR?=	NH3YVVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CHL-1	NE\iW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\kSWJKSzVyPUSuN\|IyPjlizszN	MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	NWTCclhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTRwM{OxOVMh\|ryP	M{Tlb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H661	M163ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTRwNUCwPVIh\|ryP	M{jabFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
EW-11	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXwTItSUUN3ME20MlUzOjNzIN88US=>	M1zRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BEN	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\MbVl4UUN3ME20MlUzQDF3IN88US=>	NI\KfHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BFTC-909	M3jiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2juWmlEPTB;ND61OlI4PSEQvF2=	NF7WdY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2087	NXnDbYszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\uNZJKSzVyPUSuOVgyPjRizszN	NFnNTXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RVH-421	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX6cJlKSzVyPUSuOlY3QSEQvF2=	NH3hSVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
P30-OHK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTRwNkiwNFgh\|ryP	M3LVS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H28	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HOTGlEPTB;ND64NVY3OSEQvF2=	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HTW2lEPTB;ND64N\|AyPiEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
769-P	NEDPbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLpVnpnUUN3ME20Mlg2QTJ4IN88US=>	NGXQXGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
OE33	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrYPJlGUUN3ME20Mlg5OTZzIN88US=>	NFG0TII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SW982	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTubmpKSzVyPUSuPVUxPjFizszN	NF;kRow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A388	NW\IUHhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTVwMEK5PFMh\|ryP	MmfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TI-73	NGjOeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvJPZFKSzVyPUWuNFYyQTRizszN	MlzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HCT-116	NUPENWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHHcGVKSzVyPUWuNFk5QDlizszN	NFH0e5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HuP-T3	NXjEUVB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PtbGlEPTB;NT6xPFcxQSEQvF2=	NYrwVIo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
G-402	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fUZmlEPTB;NT6xPVQyPiEQvF2=	Mn3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1792	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzHTWM2OD13LkK0OlIzKM7:TR?=	NXixbGZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H209	NFTXRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXadG5KSzVyPUWuNlU6PDJizszN	NFPv[489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1650	NUDJTVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfkTWM2OD13LkOwOlM1KM7:TR?=	M4\hclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LCLC-97TM1	NXnveFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HtcmlEPTB;NT6zNVgxQCEQvF2=	NWTlTI8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
S-117	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYWxcHdKUUN3ME21MlM3QTd4IN88US=>	NILvOnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GI-ME-N	NWj1dXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIexbWRKSzVyPUWuN\|k3QDFizszN	NHv3SnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2122	M17ZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTVwNEmzPVch\|ryP	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1793	NWP5TGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\HSo1kUUN3ME21MlY4PTl\|IN88US=>	M{\oc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
C2BBe1	NWT0W2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoL2TWM2OD13LkewNFg5KM7:TR?=	NHHI[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TE-12	M3fURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DpemlEPTB;NT64NFU2PiEQvF2=	M3;GcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LCLC-103H	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\We2lEPTB;NT65NVch\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A673	M{\YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTVwOUG5N\|Ih\|ryP	NHTzbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BB30-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X0NWlEPTB;NT65PFM3KM7:TR?=	NXzrVGh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SF295	NUT0NppOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrXfGlJUUN3ME22MlAxPDJ{IN88US=>	M{jkblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KU-19-19	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDpelZKSzVyPU[uNFE4OzFizszN	NFLBR4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CFPAC-1	NWfzSJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjYV4JKSzVyPU[uNFQ1PDNizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LoVo	M3zuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTVTWM2OD14LkC1NFY{KM7:TR?=	M{TWUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
8505C	NHXOVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnlXHBjUUN3ME22MlA4PTd\|IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
GMS-10	NUjmSno1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4GwfGlEPTB;Nj6xOVAxOiEQvF2=	NWGwSod5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
Ca9-22	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j5R2lEPTB;Nj6xOlcyKM7:TR?=	M3Lr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DOK	NYPlTVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvnTWM2OD14LkKyNFczKM7:TR?=	Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
FADU	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z3V2lEPTB;Nj6yOlA{QSEQvF2=	M3u3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BxPC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlThTWM2OD14LkK3N\|Ih\|ryP	M{T2eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-33	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTZwMkmyNFEh\|ryP	Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SHP-77	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPNSFZKSzVyPU[uN\|E2OTJizszN	NVvxdWxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LXF-289	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPydWZ7UUN3ME22MlM{PDV3IN88US=>	NULleoRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
GB-1	M4TB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfETWM2OD14LkO4NkDPxE1?	NH[y[Ws9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KS-1	M4W1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnIc2xKSzVyPU[uN\|g1PDdizszN	NFnwWIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-502MG	NFjKU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHezfVRKSzVyPU[uOFI{PzZizszN	M2rReFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LAN-6	M4HCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rIdGlEPTB;Nj61NVAzOyEQvF2=	MljXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	NUTwXFBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP1T3p2UUN3ME22MlU3OTR5IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LC-2-ad	M4Dxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITiXW9KSzVyPU[uOlAxPzZizszN	M4DZeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1693	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvCTWM2OD14Lk[yNlE2KM7:TR?=	NV3yNJlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-N-FI	NVexZXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzFTWM2OD14Lke1NFQ1KM7:TR?=	NIrVNWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-423MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;rWmlEPTB;Nj63OlEyPyEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KNS-42	NX;XWVlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPCTWM2OD14Lke4NVk4KM7:TR?=	M3PaeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
GCT	NG\5[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjsPYIzUUN3ME22Mlk{QCEQvF2=	NIq2T2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DSH1	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfMfmhKSzVyPUeuNFY{OyEQvF2=	NXrWUnFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
D-247MG	NUT3OoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTdwMEe4PFEh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-SNU-5	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHX0flZKSzVyPUeuNVg{PzFizszN	NHfIZ4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TE-6	M{HxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTdwMkC2NFEh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NOMO-1	MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4izZmlEPTB;Nz6yNlEzPyEQvF2=	NGjWOHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NB17	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITsbGpKSzVyPUeuN\|A{ODlizszN	NGfsUnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EW-22	NXXObZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTdwM{SzOFgh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EW-13	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3X6TWlEPTB;Nz6zOVE3OiEQvF2=	M2e3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DOHH-2	M3:4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnxe2tjUUN3ME23MlQ1ODJizszN	NFzPTYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TGBC1TKB	M2DsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXXTWM2OD15LkS5PFk6KM7:TR?=	NYTYcIZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
GR-ST	M3nvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3RbG9HUUN3ME23MlUzPTl2IN88US=>	M1r3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KYSE-520	M1TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHHTWM2OD15LkW1OVE2KM7:TR?=	MnnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAPAN-1	M2LWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7DTWM2OD15LkW5OVEh\|ryP	NIjJRmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HCE-4	NXfFfZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fh[WlEPTB;Nz62NlI4QSEQvF2=	M{O3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MLMA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXMcFRKSzVyPUeuOlI6PTdizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HT-144	NF3UPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fpOGlEPTB;Nz62OVM3QCEQvF2=	NXP0W2E5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KYSE-180	M{Trc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXlTWM2OD15LkexNVY6KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TE-5	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTdwOUW5O\|Eh\|ryP	M4\U[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
IGROV-1	NWL4UnlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWq2c3ZTUUN3ME23Mlk5PTVzIN88US=>	M2XUV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1581	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLmfHh5UUN3ME24MlAyOiEQvF2=	NYno[mZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1990	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEC0[mxKSzVyPUiuNFQ3PTlizszN	NV7lUnVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EFM-19	M1X2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRThwMEi1OFUh\|ryP	NGDa[JE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
OGR-1	NV3BUFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDLZ3dKSzVyPUiuOFMxOjNizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-118-MG	NWXY[GF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFf2eFZKSzVyPUiuOFM1PjNizszN	MmPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SK-OV-3	NHTLZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRThwNE[3OlUh\|ryP	NXHyUYV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KNS-62	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PtWmlEPTB;OD61NVc3OSEQvF2=	MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GOTO	NX[5Z2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzKTWM2OD16LkW3OlM2KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
8305C	M1;5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LKcGlEPTB;OD63NFQ5PCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RPMI-2650	NYPROJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M16yemlEPTB;OD63NVk2PSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NEC8	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHQTWM2OD16Lke0N\|A4KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-450	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRThwOE[1OFgh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RMG-I	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3NbmtOUUN3ME25MlE1ODV6IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAKI-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWC2NnJyUUN3ME25MlMyQTd7IN88US=>	Mk\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-510	NG\F[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoGxTWM2OD17LkO1O\|c5KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A4-Fuk	NFLidmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\EOHFqUUN3ME25MlM3PzBzIN88US=>	M4P1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AN3-CA	NETOXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTlwNEW0OFQh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-N-DZ	M1\SOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTlwN{K4OFkh\|ryP	Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HSC-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LqWGlEPTB;OT63OlYzQSEQvF2=	NFTDOW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EW-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDmc41oUUN3ME25Mlc6OzZ7IN88US=>	NI\2Nos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-566MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHPZ5dKSzVyPUmuPFM3PjRizszN	NXi0cG9oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COLO-792	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTlwOUi3OFYh\|ryP	NV:wTHlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TE-10	NI\PNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLqRW9MUUN3ME2xNE4xOzl4IN88US=>	NETp[Ys9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H650	NUXXW2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nScGlEPTB;MUCuOFI5PiEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-266	M3zj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfUV3BKSzVyPUGwMlQ2PSEQvF2=	NHzVdFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Detroit562	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPXeZRKSzVyPUGxMlA2OTVizszN	MmT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NH-12	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;5S2lEPTB;MUGuNVQ1PiEQvF2=	M3HxR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CO-314	NXL6NZN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELuclVKSzVyPUGxMlI5PDJizszN	Mmn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HRWmlEPTB;MUGuOVMzOyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KNS-81-FD	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnuTWM2OD1zMT61OVI4KM7:TR?=	NYnWeFBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1463	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHjc2ZQUUN3ME2xNU42QTh7IN88US=>	M{G4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H23	NHrUNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\ITWM2OD1zMT62OVUzKM7:TR?=	NIHZNoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-MEL-2	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[1UmVKSzVyPUGxMlcyQTdizszN	MnfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB13	NHXXR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvNTWM2OD1zMj6xOFk2KM7:TR?=	MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Daoy	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PKfGlEPTB;MUKuNlg2PiEQvF2=	Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1623	M1vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrNTWM2OD1zMj6zPFAyKM7:TR?=	NVvNW\|ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NMC-G1	M3S3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLqTWM2OD1zMj63NVch\|ryP	M1y0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DK-MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\CTWM2OD1zMj65OFgzKM7:TR?=	NYP5Z3NYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TCCSUP	M{XmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF\|LkGyPFQh\|ryP	NYHON3ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SCC-15	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzLTWM2OD1zMz6yOlUyKM7:TR?=	M4LxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NOS-1	M1[4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULLNoFRUUN3ME2xN{4zQDl\|IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RH-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF\|LkOwN\|ch\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-MEL-3	NHTWSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGGxNmpKSzVyPUGzMlM4OjhizszN	NWrVTJBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NB5	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrr[ZhqUUN3ME2xN{41ODZ5IN88US=>	NGWzfYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SNU-387	M2Wxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXO[WY3UUN3ME2xN{42ODd{IN88US=>	M3XjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-120	NVTVOnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkniTWM2OD1zMz62O\|E5KM7:TR?=	M1PtelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Mo-T	NYGxZnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPRTWM2OD1zMz63NFch\|ryP	MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LNCaP-Clone-FGC	M3LN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTF\|Lke5PVIh\|ryP	MmLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAN	M4XJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF2LkCyPFgh\|ryP	M3PSclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-30	M4nrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{G0V2lEPTB;MUSuNFY{KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
COLO-678	NYDHUoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHvV5ZWUUN3ME2xOE4xQDJ{IN88US=>	NUf0UGhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SCC-9	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTiZWVzUUN3ME2xOE4yODJzIN88US=>	M3vHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KINGS-1	M1LFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\PUnQzUUN3ME2xOE4yPDB{IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SL-513	NUnjcGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4WwTGlEPTB;MUSuNVg4KM7:TR?=	NULIepVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HLE	NHHHNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjSeIVKSzVyPUG0MlM5PTJizszN	M1jMb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW1573	NIDkeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonGTWM2OD1zND60OFM2KM7:TR?=	M{\BO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KYSE-140	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTF2Lk[zNlch\|ryP	Ml7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	NVK0XpUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTF2LkiwNFEh\|ryP	NWKzc3hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A253	M3\KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnm5TWM2OD1zNT6wOlI2KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-12T	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT5VFBKSzVyPUG1MlQ3PjJizszN	NWCxOFdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COLO-679	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXyfm9pUUN3ME2xOU44Pjh\|IN88US=>	MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
UACC-257	NXX1fYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF4LkGyNFEh\|ryP	M{fmeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
U-87-MG	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTF4LkO1NlMh\|ryP	NETOVlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HCC1806	NEjxXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF4LkewO\|Eh\|ryP	MlTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2170	NHL2NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF5LkK0OFgh\|ryP	NFrxNXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
AGS	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXWN\|RIUUN3ME2xO{4{QDB6IN88US=>	NEnHe2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MEL-HO	NHLuWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTGPFZKSzVyPUG3Mlc2ODNizszN	MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SW48	NWLkZWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF5Lke3NVYh\|ryP	NEeweJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HuP-T4	NXXNVIF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;kXmlEPTB;MUiuNFIxPiEQvF2=	NFezXYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H720	NV[yUYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmP2TWM2OD1zOD6xOFAzKM7:TR?=	Ml;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RCC10RGB	NGnjb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPhTWM2OD1zOD6xOlk4KM7:TR?=	M1q1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HD-MY-Z	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jB[2lEPTB;MUiuNlI2PCEQvF2=	NFS2dZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A427	NGHMPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELDcGNKSzVyPUG4MlUxQTRizszN	NEnKTnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HCC2998	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXj[lZ1UUN3ME2xPE43ODVzIN88US=>	NHnnXlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EPLC-272H	M1XCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3u2[2lEPTB;MUmuNFQ{PCEQvF2=	NXjLVZd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
C32	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;XTWM2OD1zOT6wOFUh\|ryP	M3zjWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
UMC-11	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\HRWlEPTB;MUmuNlEzOyEQvF2=	M4DZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CaR-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvUTWM2OD1zOT62PFA1KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-410	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XYZ2lEPTB;MUmuPVE{QSEQvF2=	NWH4bYo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HuCCT1	NYD5VVRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[1[GlEPTB;MkCuOlI6PCEQvF2=	NF:zVZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LB996-RCC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJyLkexOlgh\|ryP	M4TGclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KYSE-70	NH;YS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJyLkiwOVkh\|ryP	M1G0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-72	NVT5O\|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJyLkmxOUDPxE1?	Mlq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Capan-2	NWrOV2RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nmRWlEPTB;MkGuNFQyOyEQvF2=	NV3tTo05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
PANC-08-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfTTWM2OD1{MT6yOVE2KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SBC-1	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjHcXNKSzVyPUKxMlMxQDFizszN	NYTod\|c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MFM-223	NULCXoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJzLkOzOFIh\|ryP	M3PrbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BB49-HNC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFu1cmFKSzVyPUKxMlU4OTZizszN	MnnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SH-4	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjk[3hKSzVyPUKxMlY3OThizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HuO9	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTJzLkm4NlUh\|ryP	M1HrbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AM-38	NY[5[G9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rKSmlEPTB;MkKuNFQ5PSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A431	NGCzSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rpT2lEPTB;MkOuNlEyQSEQvF2=	MkHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
YAPC	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVK2UWdsUUN3ME2yN{4zPjVzIN88US=>	MmHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-139	NXHITWdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ\|LkS4NFkh\|ryP	NHG2TVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HEC-1	NIHqdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzKfHNPUUN3ME2yN{41QTN5IN88US=>	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SCC-25	M3TTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvKbHBKSzVyPUK0MlMxODZizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HT-29	NIXW[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHCT5NGUUN3ME2yOE4{QDJ\|IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
PC-14	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;i[mZpUUN3ME2yOE43PTdzIN88US=>	NE\4WoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Calu-6	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnI[4hYUUN3ME2yOU42ODdzIN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SJRH30	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnaSpRKSzVyPUK1MlY1QTZizszN	MmHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1	NHvVO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fsU2lEPTB;Mk[uNVYzQSEQvF2=	M1HJXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
IA-LM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYribmpZUUN3ME2yOk4{PjR3IN88US=>	MonXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GP5d	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ4LkS0PVEh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2291	NYK2TYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJ4Lk[1OFEh\|ryP	NVv5c402RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BALL-1	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJ4LkmzPVch\|ryP	NWLUT21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HCC1954	NX\LR5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTDTWM2OD1{Nj65PFA5KM7:TR?=	Mmf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2452	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ5LkSxOlMh\|ryP	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-99A	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[zOmlEPTB;MkeuOVU5OiEQvF2=	MnLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NETB[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4W2bGlEPTB;MkeuO\|I6QSEQvF2=	M3;vU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
PANC-10-05	M3rpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfBV5hKSzVyPUK3Mlc4PzVizszN	NWXGbWN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H2405	M4nxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ5LkmzPFch\|ryP	MmHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-415	NFLDS\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;zeIVKSzVyPUK4MlQyOzdizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2342	M1nPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LIUGlEPTB;MkiuOVI5OSEQvF2=	NFvFXng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TGBC24TKB	NXXNTYY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\VS2lEPTB;MkiuO\|EyPyEQvF2=	MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-134-A	M33NT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HtNWlEPTB;MkiuPVI3OSEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SCC-4	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vFd2lEPTB;M{GuNFQ6PCEQvF2=	MmXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Saos-2	NELGbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPjTWM2OD1\|MT65N\|A3KM7:TR?=	NUHObHg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RERF-LC-MS	NWjWOYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnOOGhuUUN3ME2zNk45OjNzIN88US=>	Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
M14	M4Xxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTTTWM2OD1\|Mj65O\|Y1KM7:TR?=	M1XPNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HPAF-II	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHU[nhKSzVyPUOzMlUxOTFizszN	NVfG[JpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1755	M{jSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3VXohKSzVyPUO0MlM{ODVizszN	Mmf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
D-392MG	NYe0d2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnBZXVVUUN3ME2zOU45Pjd2IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A704	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjMfpd{UUN3ME2zOk4xPDJ5IN88US=>	NGf3[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CP50-MEL-B	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTN4LkG5NVEh\|ryP	Ml\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-18	NGrPPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDRTWM2OD1\|Nj60OVIh\|ryP	NI\Y[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
WM-115	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTN4LkiwPVkh\|ryP	Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-65	M{TWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnjTWM2OD1\|Nz6xOFE4KM7:TR?=	NH;IWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1563	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7zZpNKSzVyPUO3MlI1QDRizszN	M{\1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DBTRG-05MG	NEXHUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\WflRKSzVyPUO4MlA3QTFizszN	M{P0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H630	M3;1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLrWpRKSzVyPUO4MlQ4OTRizszN	NH7NTWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1155	NVrtNlY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDWWHRKSzVyPUO5MlI1OiEQvF2=	NV;aN4hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
OVACR-3	M2DacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4niWGlEPTB;M{muPVE6PSEQvF2=	M1m0WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;yVIo2UUN3ME20NE41OjV6IN88US=>	NWHtW\|huRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
JVM-2	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mor0TWM2OD12MT6yOFE2KM7:TR?=	NIS0TI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
C3A	NFrmfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVK3eYVKUUN3ME20NU4{PDR5IN88US=>	M33s[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HT55	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLQTWM2OD12Mj6yPFQyKM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
OVCAR-4	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjYUYd{UUN3ME20Nk4zQTd2IN88US=>	NIHLcnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MEG-01	NYP2TXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXqzXZZ[UUN3ME20Nk41PjF4IN88US=>	M4nlVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H82	M{T0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTR\|Lkm4PVIh\|ryP	NGWxdHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
JEG-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTR2Lkm0O{DPxE1?	M3niS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BPH-1	M3;VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDWTWM2OD12Nj6zPVk5KM7:TR?=	NVPPcpRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MPP-89	M1XQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\6TWM2OD12Nz6yPFk5KM7:TR?=	NX7wb\|NiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ALL-PO	NXSweY1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\ONWlEPTB;NEeuOFE5QCEQvF2=	NXLBbZg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HT	M4rQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPw[\|FFUUN3ME20O{41QTJizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2347	NHLqSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHj5UYtKSzVyPUS4MlA4OTVizszN	MnHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A2780	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTR7LkSyNlgh\|ryP	M3WwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KARPAS-299	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHJXFVKSzVyPUS5MlUyOTlizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H1651	NFjOTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDNTWM2OD12OT64PFIyKM7:TR?=	M{nVSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04669587	Not yet recruiting	Drug: ZB716\|Drug: Palbociclib	Estrogen Receptor-Positive\|HER2-Negative\|Advanced\|Metastatic Breast Cancer	EnhancedBio USA Inc.\|Zenopharm LLC\|EnhancedBio Inc.	February 1 2021	Phase 1\|Phase 2
NCT04671615	Active not recruiting	Drug: palbociclib	Metastatic Breast Cancer	Pfizer	December 6 2020	--
NCT04567420	Not yet recruiting	Drug: Palbociclib\|Drug: Fulvestrant\|Drug: Adjuvant Therapy	Breast Cancer	Criterium Inc.	December 15 2020	Phase 2
NCT04654208	Not yet recruiting	Drug: palbociclib	Malignant Neoplasm of Breast	Pfizer	November 30 2020	--
NCT04483505	Recruiting	Drug: Combination Rogaratinib + palbociclib + fulvestrant	Breast Cancer Metastatic\|Hormone Receptor Positive Malignant Neoplasm of Breast	Fundacion CRIS de Investigación para Vencer el Cáncer\|Bayer\|Pfizer\|Apices Soluciones S.L.	November 25 2020	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl (NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (Seliciclib)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl